(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Aligos Therapeutics's earnings in 2025 is -$86,462,000.On average, 6 Wall Street analysts forecast ALGS's earnings for 2025 to be -$51,259,338, with the lowest ALGS earnings forecast at -$54,576,119, and the highest ALGS earnings forecast at -$49,170,197. On average, 6 Wall Street analysts forecast ALGS's earnings for 2026 to be -$45,647,271, with the lowest ALGS earnings forecast at -$52,465,440, and the highest ALGS earnings forecast at -$32,047,855.
In 2027, ALGS is forecast to generate -$42,618,478 in earnings, with the lowest earnings forecast at -$58,194,425 and the highest earnings forecast at -$25,005,080.